Delivery Order SPE2DB25D3012-SPE2DB25FXAPE
- Not listed
- AmerisourceBergen Drug Corp, a major pharmaceutical distributor headquartered in Conshohocken, Pennsylvania, was awarded a competitive delivery order valued at $11,895.72 by the Defense Logistics Agency on July 22, 2025, for the supply of INLYTA 5 mg tablets in quantities of 60 units. The contract, which carries a firm fixed-price structure with an ultimate completion date of August 12, 2025, represents a child delivery order under AmerisourceBergen's larger Indefinite Delivery Contract (IDC)...
- The Defense Logistics Agency awarded a $11,895.72 delivery order to AmerisourceBergen Drug Corp for INLYTA 5 mg tablets (60-count units) on August 19, 2025, with an ultimate completion date of September 10, 2025. This firm fixed-price contract represents a non-competitive set-aside delivery order issued under AmerisourceBergen's existing Indefinite Delivery Contract with DLA Troop Support Medical (SPE2DX), a $999.99 billion global pharmaceutical support vehicle running through December 2026. The...
- The Defense Logistics Agency awarded a delivery order valued at $11.9K to AmerisourceBergen Drug Corp on September 11, 2025, for the supply of Inlyta 5 mg tablets (60-count units). The contract is firm fixed price with an ultimate completion date of October 2, 2025, and carries no set-aside designation, indicating it was competitively awarded. AmerisourceBergen, headquartered in Conshohocken, Pennsylvania, is a major pharmaceutical distributor serving federal medical procurement needs across...
- The Defense Logistics Agency awarded a $23.79K delivery order to AmerisourceBergen Drug Corp on September 24, 2025, for the supply of INLYTA 5 MG tablets (60-count units). This firm fixed-price, non-competitive delivery order is scheduled for completion by October 16, 2025, with performance at the contractor's Conshohocken, Pennsylvania facility. As a child delivery order, this award is issued under AmerisourceBergen's existing Indefinite Delivery Contract (SPE2DX) with DLA Troop Support...
- The Defense Logistics Agency awarded a $11,895.72 firm fixed-price delivery order to AmerisourceBergen Drug Corp for 60 tablets of INLYTA 5 mg, a pharmaceutical product used in cancer treatment. This non-competitive delivery order, issued on September 4, 2025, will be fulfilled at the company's corporate headquarters in Conshohocken, Pennsylvania, with an ultimate completion date of September 25, 2025. The award represents a routine pharmaceutical procurement supporting federal medical supply...
- AmerisourceBergen Drug Corp, headquartered in Conshohocken, Pennsylvania, was awarded a delivery order valued at $11.9K by the Defense Logistics Agency (DLA) on June 2, 2025, for the supply of INLYTA 5 mg tablets (60-count units). This is a firm fixed-price, non-set-aside contract with an ultimate completion date of June 24, 2025. The award represents a child contract under AmerisourceBergen's larger Indefinite Delivery Contract (IDC) with DLA Troop Support Medical (SPE2DX), a $1.0B global...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp for $71,374.32 to supply 60 tablets of INLYTA 5 mg, a pharmaceutical product, with performance at the company's Conshohocken, Pennsylvania facility. The award, issued on September 12, 2025, carries a completion date of October 3, 2025, and utilizes firm fixed pricing without any set-aside designation. This delivery order represents a competitive award to the prime contractor under an existing contract vehicle....
- The Defense Logistics Agency awarded a delivery order valued at $11,895.72 to AmerisourceBergen Drug Corp for INLYTA 5 mg tablets (60-count packaging) on September 11, 2025, with an ultimate completion date of October 2, 2025. This firm fixed-price delivery order was competitively awarded with no set-aside designation and will be performed at the contractor's corporate office location in Conshohocken, Pennsylvania. AmerisourceBergen Drug Corp, a major pharmaceutical distributor and critical...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp for $23,847.20 to supply 180 tablets of INLYTA 1 mg, a pharmaceutical product for cancer treatment. This non-competitive, firm fixed-price delivery order was awarded on June 5, 2025, with a completion date of June 27, 2025. The place of performance is AmerisourceBergen's corporate office in Conshohocken, Pennsylvania. This delivery order is a child contract under AmerisourceBergen's larger Indefinite Delivery...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on August 15, 2025, for the supply of INLYTA 5 mg tablets (60-count units) with a ceiling value of $11,895.72. This firm fixed price delivery order, with an ultimate completion date of September 8, 2025, represents a competitive award with no set-aside designation. AmerisourceBergen Drug Corp, headquartered in Conshohocken, Pennsylvania, is a major pharmaceutical distributor serving federal medical procurement...
- SPE2DB25D3012Indefinite Delivery Contract
- SPE2DB25D3012-SPE2DB25FXAPEDelivery Order
The Defense Logistics Agency awarded a $23,791.44 firm fixed-price delivery order to AmerisourceBergen Drug Corp on September 26, 2025, for the supply of INLYTA 5 mg tablets (60 count). The contract, which is non-set-aside and competitively awarded, designates Conshohocken, Pennsylvania as the place of performance and carries an ultimate completion date of October 20, 2025. This delivery order is issued under AmerisourceBergen's larger Indefinite Delivery Contract (IDC) with DLA Troop Support Medical, designated SPE2DX, which is valued at $999,999,999.00 and extends through December 2026. AmerisourceBergen Drug Corp, a major pharmaceutical distributor headquartered in Conshohocken, Pennsylvania, serves as a critical vendor for federal medical procurement through the DLA's Medical Supply Chain. The company's extensive federal contract portfolio demonstrates its capability to supply a comprehensive range of pharmaceutical products and medical supplies to military and veteran healthcare systems, including brand-name and generic medications, vaccines, medical devices, and specialized healthcare commodities across multiple therapeutic domains. INLYTA (axitinib), a targeted cancer therapy, represents one of many specialty medications the company delivers to support military healthcare programs globally through its flexible IDC vehicle.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | Not listed | $23.8k | 9/26/25 |